Publications by authors named "Miles A Stewart"
The increasing threat of emerging and re-emerging pathogens calls for a shared vision toward developing and maintaining global surveillance mechanisms to enable rapid characterization of pathogens, a foundational requirement for effective outbreak response. Efforts establishing new surveillance programs in low- and middle-income countries (LMICs) have repeatedly led to siloed systems that prove unsustainable or ineffective due to narrowly focused approaches, competing priorities, or lack of resourcing. Barriers inherent to LMICs, such as resource limitations, workforce strain, unreliable supply chains, and lack of enduring champions exacerbate implementation and sustainability challenges.
View Article and Find Full Text PDFArticle Synopsis
- - The COVID-19 pandemic strained healthcare systems, prompting the development of a web-based decision-support tool aimed at optimizing staffing and capacity for monoclonal antibody (mAb) infusion facilities.
- - A discrete-event simulation model was created based on real-world data from three medical centers, evaluating 162,000 scenarios to determine the most effective staffing strategies and appointment scheduling for mAb infusions.
- - Findings indicated that adding check-in staff and optimizing infusion time are crucial for operational efficiency, suggesting that health systems can effectively manage mAb infusion centers with minimal resource investment to better treat COVID-19 patients.
Monoclonal antibody therapeutics to treat coronavirus disease (COVID-19) have been authorized by the US Food and Drug Administration under Emergency Use Authorization (EUA). Many barriers exist when deploying a novel therapeutic during an ongoing pandemic, and it is critical to assess the needs of incorporating monoclonal antibody infusions into pandemic response activities. We examined the monoclonal antibody infusion site process during the COVID-19 pandemic and conducted a descriptive analysis using data from 3 sites at medical centers in the United States supported by the National Disaster Medical System.
View Article and Find Full Text PDFArticle Synopsis
- Monoclonal antibodies (mAbs) show promise in treating COVID-19 by reducing hospitalizations and emergency visits, but their use is limited, especially among disadvantaged groups.
- A study analyzed electronic health records of COVID-19 patients at a medical center, comparing those treated with mAbs to untreated patients from before the treatments were available.
- Results indicated that treated patients had a significantly lower risk (82% less) of hospitalization or emergency visits compared to untreated patients, emphasizing the need for equitable access to mAb treatment across all demographics.